Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN
Published: July 1st 2024 | Updated: July 1st 2024The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]
The Persistent Burden of Migraine Despite Treatment Advances: Amaal Starling, MD, FAHS, FAAN
March 20th 2024The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about the significant disease burden experienced by patients with migraine even as therapeutics have advanced for the condition. [WATCH TIME: 8 minutes]
Patient-Centered Care to Address Symptoms in Migraine Treatment: Amaal Starling, MD, FAHS, FAAN
January 14th 2024The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about the importance of adopting a patient-centered approach in migraine treatment and the often overlooked impact of brain fog in patients with migraine. [WATCH TIME: 4 minutes]
Eptinezumab’s Real-World Impact as Chronic Migraine Treatment: Amaal Starling, MD, FAHS, FAAN
November 28th 2023The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about findings from a real-world study assessing eptinezumab among patients with chronic migraine which was presented at the AHS Scottsdale Headache Symposium 2023. [WATCH TIME: 4 minutes]